Phase I/II Study Exploring Safety and Efficacy of Apl-101 Plus Frontline Osimertinib in EGFR-mutated Metastatic Non-small Cell Lung Cancer

被引：0
|
作者：
Patel, B. [1 ]
Wu, N. [1 ]
Myles, S. [1 ]
Turlington, D. [1 ]
Yu, P. [2 ]
Saha, G. [2 ]
Rohatgi, A. [1 ]
Herzog, B. H. [1 ]
Ward, J. P. [1 ]
Baggstrom, M. Q. [1 ]
Waqar, S. N. [1 ]
Morgensztern, D. [1 ]
Govindan, R. [1 ]
Devarakonda, S. [1 ]
机构：
[1] Washington Univ, St Louis, MO 63110 USA
[2] Apollomics Inc, Foster City, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
MET TKI; EGFR TKI; Phase I/II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-41
引用
收藏
页码：S350 / S350
页数：1
相关论文
共 50 条
  • [21] A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)
    Zhang, L.
    Fang, W. F.
    Zhao, S.
    Yu, Y.
    Yong, T. X.
    Dong, X.
    Zhuang, W.
    Hu, Y.
    Luo, F.
    Wang, Q.
    Chu, Q.
    Fu, Z.
    Yao, Y.
    Ma, X.
    Ding, C.
    Hao, J.
    Yang, X.
    Wan, X.
    Li, M.
    Yang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1624 - S1625
  • [22] Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
    Saboundji, Karima
    Auliac, Jean-Bernard
    Perol, Maurice
    Francois, Geraldine
    Janicot, Henri
    Marcq, Marie
    Dubos-Arvis, Catherine
    Renault, Aldo
    Guisier, Florian
    Odier, Luc
    Gervais, Radj
    Chouaid, Christos
    TARGETED ONCOLOGY, 2018, 13 (04) : 501 - 507
  • [23] Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
    Karima Saboundji
    Jean-Bernard Auliac
    Maurice Pérol
    Géraldine François
    Henri Janicot
    Marie Marcq
    Catherine Dubos-Arvis
    Aldo Renault
    Florian Guisier
    Luc Odier
    Radj Gervais
    Christos Chouaïd
    Targeted Oncology, 2018, 13 : 501 - 507
  • [24] A population-adjusted indirect treatment comparison of efficacy and safety of aumolertinib vs osimertinib in EGFR-mutated non-small cell lung cancer
    King, Sarah
    Stergiopoulos, Stella
    Curtis, Melissa
    Dillon, Andrew
    Akehurst, Ron
    Lee, Dawn
    Guelfucci, Florent
    Ngami, Armel
    Bianic, Florence
    Li, You
    Ma, Xiwen
    Ali, Siraj
    Miller, Vincent
    Popat, Sanjay
    LUNG CANCER, 2023, 178 : S36 - S37
  • [25] Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)
    Araki, Taisuke
    Kanda, Shintaro
    Komatsu, Masamichi
    Sonehara, Kei
    Tateishi, Kazunari
    Takada, Munetake
    Kato, Akane
    Yamamoto, Manabu
    Nishie, Kenichi
    Hama, Mineyuki
    Agatsuma, Toshihiko
    Kakizaki, Yumiko
    Yoshiike, Fumiaki
    Matsuo, Akemi
    Chiaki, Tomoshige
    Samizo, Kanae
    Takagi, Yoshiko
    Yamaura, Maki
    Hanaoka, Masayuki
    Koizumi, Tomonobu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (06) : 1320 - 1327
  • [26] Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
    Patel, Shruti R.
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1631 - 1635
  • [27] Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
    Calvo, Emiliano
    Lee, Jong-Seok
    Kim, Sang-We
    Moreno, Victor
    deCastro Carpeno, Javier
    Weilert, Doris
    Laus, Gianluca
    Mann, Helen
    Vishwanathan, Karthick
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08): : 1099 - 1109
  • [28] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [29] Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer
    Tian, Wentao
    Niu, Lishui
    Zhou, Rongrong
    Wang, Ziqi
    Ning, Jiaoyang
    Lu, Ruoyu
    Shi, Yin
    Tan, Zhaohua
    CANCER MEDICINE, 2024, 13 (16):
  • [30] Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
    Rotow, Julia K.
    Costa, Daniel Botelho
    Paweletz, Cloud P.
    Awad, Mark M.
    Marcoux, Paul
    Rangachari, Deepa
    Barbie, David Allen
    Sands, Jacob
    Cheng, Michael L.
    Johnson, Bruce E.
    Oxnard, Geoffrey R.
    Jackman, David Michael
    Kwiatkowski, David J.
    Kehl, Kenneth L.
    Izdebski, Monika D.
    Lau, Christie J.
    Vasquez, Kevin A.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345